Related Experiment Video
Updated: Jun 21, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Abstract:
(1) According to the WHI trial, postmenopausal hormone replacement therapy exposes women to an additional risk of breast cancer of about 8 cases a year per 10 000 treated women; (2) In the United States, a comparison of the breast cancer incidence rates in 2001 and 2004 showed an overall annual decrease of 8.6%, attributable to the reduction in the use of hormone replacement therapy in postmenopausal women. A similar phenomenon was observed in France, Germany and Canada; (3) In summary, if prescribers had waited for the results of the WHI trial, many cases of breast cancer would probably have been avoided.
Related Concept Videos
Menopause
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Disorders of the Female Reproductive System
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.